StockDrifts LogoStockDrifts

2026 Q1 · 13F Analysis

Mangrove Partners Im Llc Rotates From Credit To Crypto, Pipes, and Oligopolies

Published July 8, 2026 · Based on the SEC 13F filing for 2026 Q1

Portfolio Manager
Mangrove Partners Im LLC
Performance
-4.45% (2026 Q1)
AUM (13F)
$1.24B
# of Holdings
427
Performance Rank
Allocation (Top 20)
65.42%

Key takeaways

  • Leans into crypto, healthcare, and telecom as new cycle leaders after a soft quarter
  • Builds a barbelled book of distressed growth and boring oligopolies
  • Ages out of credit-heavy financial exposure toward harder, real-asset cash flows
  • Uses SPAC book as funding ballast, not a source of incremental risk
  • Bets that bandwidth, addiction meds, and midstream cash flows beat broad beta

The thesis in one look

Mangrove’s 2026-Q1 book reads like a manager willing to walk away from the last cycle. Finance and consumer cyclicals are getting lighter, while health care, crypto, staples, and telecom jump from the periphery into the core. The portfolio gave back 4.45% in the quarter, but the response was to re‑risk into new leaders rather than de‑gross, backed by a still-tight top‑10 concentration of 41.6%.

The emerging pattern is a barbell. On one side: highly controversial growth or special situations with big dispersion — addiction therapeutics, crypto exposure, and turnaround telecom. On the other: dull but durable oligopolies in rails, beverages, filtration, and auto parts, often bought against short‑term disappointment.

Under the surface, Mangrove is shrinking its reliance on traditional financials and listed real estate in favor of real‑asset cash flows (midstream, utilities, rails) and software/transaction rails. The SPAC complex remains a large sleeve by name count, but it is increasingly a cash‑adjacent funding pool rather than a driver of marginal risk.

Portfolio concentration
INDV — 8.7% ($83.59M)ATMU — 7.8% ($74.67M)ETH — 7.3% ($70.56M)REX — 4.8% ($46.26M)PCG — 4.4% ($42.41M)OKE — 4.3% ($41.74M)TIGO — 4.3% ($41.70M)ENVA — 4.0% ($38.92M)MRP — 4.0% ($38.67M)KDP — 3.7% ($35.93M)Other — 46.5% ($447.93M)
53%in top 10
  • INDV8.7%
  • ATMU7.8%
  • ETH7.3%
  • REX4.8%
  • PCG4.4%
  • OKE4.3%
  • TIGO4.3%
  • ENVA4.0%
  • MRP4.0%
  • KDP3.7%
  • Other46.5%

Performance History

Performance Metric3-Year Annualized3-Year Cumulative
Top 20 Holdings Weighted+32.89%+134.67%
Top 20 Holdings Unweighted+28.51%+112.25%

Fund Performance vs S&P 500

Exposure

Sector allocation

Current sector weights across the reported book, with the shift since last quarter.

Consumer Discretionary17.3%−7.1%
Unclassified16.8%+7.0%
Finance13.9%−8.3%
Industrials12.2%−2.8%
Utilities9.4%+0.5%
Health Care8.7%+8.7%
Real Estate6.8%−3.9%
Technology6.7%−2.0%
Telecommunications4.3%+4.2%
Consumer Staples3.7%+3.7%

Portfolio

Portfolio allocation

The fund's largest reported positions.

Top Holdings

Top 10 holdings

StockCompany% Port.SharesValueActivityOwnershipAvg. CostDate
INDV
INDIVIOR PHARMACEUTICALS INC
6.76%2.74M$83.6Mnew2025-Q1: 0 shares2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 2.74M shares
$13.62(+169.87%)
2026-03-31
ATMU
ATMUS FILTRATION TECHNOLOGIE
6.04%1.32M$74.7M
+0.00%(+0)
2025-Q1: 1.10M shares2025-Q2: 1.10M shares2025-Q3: 1.33M shares2025-Q4: 1.32M shares2026-Q1: 1.32M shares
$25.59(+101.77%)
2026-03-31
ETH
GRAYSCALE ETHEREUM STAKING
5.71%3.55M$70.6Mnew2025-Q1: 0 shares2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 3.55M shares
$23.96(-11.94%)
2026-03-31
REX
REX AMERICAN RES CORP
3.74%1.02M$46.3M
+0.00%(+0)
2025-Q1: 0 shares2025-Q2: 0 shares2025-Q3: 526.6K shares2025-Q4: 1.02M shares2026-Q1: 1.02M shares
$29.40(+70.25%)
2026-03-31
PCG
PG&E CORP
3.43%2.41M$42.4M
+0.00%(+0)
2025-Q1: 0 shares2025-Q2: 0 shares2025-Q3: 2.60M shares2025-Q4: 2.41M shares2026-Q1: 2.41M shares
$14.51(+11.16%)
2026-03-31
OKE
ONEOK INC NEW
3.38%461.7K$41.7Mnew2025-Q1: 0 shares2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 461.7K shares
$82.05(+12.52%)
2026-03-31
TIGO
MILLICOM INTL CELLULAR S A
3.38%556.5K$41.7M
+7091.59%(+548.75K)
2025-Q1: 1.08M shares2025-Q2: 1.08M shares2025-Q3: 0 shares2025-Q4: 7.7K shares2026-Q1: 556.5K shares
$64.66(+22.59%)
2026-03-31
ENVA
ENOVA INTL INC
3.15%286.5K$38.9M
+0.00%(+0)
2025-Q1: 415.2K shares2025-Q2: 415.2K shares2025-Q3: 497.0K shares2025-Q4: 286.5K shares2026-Q1: 286.5K shares
$47.36(+246.33%)
2026-03-31
MRP
MILLROSE PPTYS INC
3.13%1.38M$38.7M
+0.00%(+0)
2025-Q1: 1.19M shares2025-Q2: 1.19M shares2025-Q3: 1.44M shares2025-Q4: 1.38M shares2026-Q1: 1.38M shares
$27.30(-2.16%)
2026-03-31
KDP
KEURIG DR PEPPER INC
2.91%1.36M$35.9Mnew2025-Q1: 0 shares2025-Q2: 0 shares2025-Q3: 0 shares2025-Q4: 0 shares2026-Q1: 1.36M shares
$27.17(+6.48%)
2026-03-31

Portfolio changes

What the fund actually did

Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.

New buys
15
INDVINDIVIOR PHARMACEUTICALS INC6.8%
ETHGRAYSCALE ETHEREUM STAKING5.7%
OKEONEOK INC NEW3.4%
KDPKEURIG DR PEPPER INC2.9%
+11 opened
Added to
7
TIGOMILLICOM INTL CELLULAR S A+7091.6%
TRIPTRIPADVISOR INC+4753.5%
FISFIDELITY NATL INFORMATION SV+29.6%
BILLBILL HOLDINGS INC+28.0%
+3 more
Trimmed
2
FACTFACT II ACQUISITION CORP-2.5%
IPODDUNE ACQUISITION CORP II+0.0%

Where conviction is rising: ETH, addiction meds, bandwidth, and boring moats

Look at the biggest adds and you see a manager leaning hard into non‑consensus cyclicals and new structural winners. This isn’t window dressing — it’s a deliberate reset of what drives returns here.

  • INDV (Indivior Pharmaceuticals, 6.76%, $83.6M): A top‑three stake installed in one shot. Mangrove is explicitly paying up for a controversial addiction‑treatment franchise and litigation overhang, then letting mean re‑rating do the work; the position sits about 169.9% above their average cost, suggesting they’ve been pressing strength rather than trimming success.
  • ETH (Grayscale Ethereum Staking, 5.71%, $70.6M): A new core bet that crypto infrastructure is investable, and that the next leg of returns comes from yield‑bearing ETH exposure rather than meme beta. They’re currently down about 11.9% versus cost — and have not flinched — implying they view near‑term volatility as noise, not a thesis breach.
  • OKE (ONEOK, 3.38%, $41.7M) and PCG/CIG alongside it: Building a cluster of regulated and quasi‑regulated energy and power cash flows. The OKE entry at scale signals a view that midstream volumes and dividends win in a stagflation‑ish or higher‑for‑longer backdrop.
  • TIGO (Millicom, 3.38%, $41.7M): A 7,091.6% position size jump is not tinkering — it’s a statement. Mangrove is betting that under‑invested emerging‑market telecoms finally get paid for the capex they’ve sunk into bandwidth, helped by balance‑sheet repair and asset sales.
  • KDP (Keurig Dr Pepper, 2.91%, $35.9M), UNP (Union Pacific, 2.91%, $35.9M), and GPC (Genuine Parts, 2.71%, $33.5M): A fresh trio of oligopolistic cash‑flow machines in beverages, rails, and auto parts. GPC is sitting roughly 18.8% below Mangrove’s entry, and yet it was added as a new stake — a clear signal they’re willing to underwrite near‑term mark‑to‑market pain for multi‑year pricing power.
  • BILL and FIS (both meaningfully increased) plus TRIP (up 4,753.5% in shares): they are doubling down on transaction and travel rails that have disappointed the market, with BILL and TRIP trading 18.6–25.3% below Mangrove’s average buys. This is classic value‑through‑time‑arbitrage — leaning into hated software and travel networks they believe can re‑accelerate margins.

Taken together, the “big buys” tilt the fund toward three themes: crypto and digital rails as a new asset layer, essential networks (telecom, midstream, rails) with latent pricing power, and battered but resilient consumer/SMB software.

Conviction

The big buys

The biggest dollar adds this quarter — where conviction is rising.

PositionChangePortfolio weightValue
INDVINDIVIOR PHARMACEUTICALS INCNew+$83.6M6.8%$83.6M
ETHGRAYSCALE ETHEREUM STAKINGNew+$70.6M5.7%$70.6M
OKEONEOK INC NEWNew+$41.7M3.4%$41.7M
TIGOMILLICOM INTL CELLULAR S AAdded 7091.6%+$41.1M3.4%$41.7M
KDPKEURIG DR PEPPER INCNew+$35.9M2.9%$35.9M
UNPUNION PAC CORPNew+$35.9M2.9%$35.9M
GPCGENUINE PARTS CONew+$33.5M2.7%$33.5M
TRIPTRIPADVISOR INCAdded 4753.5%+$10.1M0.8%$10.3M

Dollar changes estimated at current prices (shares added × current price); top-50 current positions only.

What they’re trimming: SPAC housekeeping, not a thesis reversal

On the surface, Mangrove’s “biggest trims” look trivial — the cuts to FACT and IPOD barely register in dollars. That’s exactly the point: this quarter’s selling is about housekeeping and funding, not about repudiating core theses.

  • FACT (FACT II Acquisition) and IPOD (DUNE Acquisition II): Reductions of 2.5% and effectively flat, respectively, free almost no capital but telegraph where conviction is not rising. These blank‑check structures are being left to amortize toward trust value rather than grown as risk assets.
  • The broader SPAC sleeve (AIIA, OYSE, APAD, INAC, etc.) is largely unchanged in share count, despite attractive marks versus Mangrove’s low entry costs. That suggests they view this bucket as a balance‑sheet tool — carry and optionality with limited downside — rather than an area to press when new ideas like INDV, ETH, and TIGO demand fresh capital.

The real “trims” this quarter are visible in the sector weights, not in individual deletions from the top‑50. Finance, real estate, and consumer discretionary collectively shrink as a share of the book, implying that exits and reductions were more meaningful in positions now too small to appear in the top‑50 set. The absence of any major core‑name liquidation is itself telling: the manager is rotating at the edges, not capitulating at the center.

How exposure is rotating: out of credit and cyclicals, into crypto and cash flows

The bar chart makes the rotation unambiguous. Finance drops from 22.21% to 13.9% of the disclosed book, while real estate falls from 10.74% to 6.85% and consumer discretionary from 24.47% to 17.34%. This is a manager walking away from credit‑sensitive and advertising‑exposed stories toward assets whose value is set more by throughput and regulation than by GDP.

On the other side of the ledger, health care goes from effectively zero to 8.69% on the back of INDV alone, and telecom leaps from 0.11% to 4.33% via TIGO. Utilities nudge up to 9.4% with the addition of OKE, while consumer staples appears as a new 3.73% sleeve anchored by KDP. These shifts point to a view that the next few years will reward companies that can either raise price on inelastic demand or are regulated to earn a fair return.

The “Unclassified” bucket swells from 9.84% to 16.84%, driven by ETH, BSOL, and a cohort of SPACs and yieldy trust‑like vehicles. Under the hood, that’s effectively an allocation to crypto, optionality, and pseudo‑cash — a barbell against the more traditional industrial and utility names. Technology edges down from 8.7% to 6.71%, but the mix inside tech shifts toward idiosyncratic event and operating‑leverage stories (BILL, TRIP, OTEX) rather than broad platform exposure.

Forward read: a portfolio positioned for choppy nominal growth and idiosyncratic upside

Put it together and Mangrove is positioning for a world of stubborn nominal growth, volatile rates, and highly dispersed equity outcomes. They are de‑emphasizing balance‑sheet and credit spread plays, and leaning into businesses whose economics ride on usage, volume, and regulated returns — rails, telecom, midstream, beverages — plus a high‑beta crypto overlay via ETH and BSOL.

The willingness to add into drawdowns (ETH, BILL, FIS, TRIP, GPC) while pressing winners like INDV and TIGO suggests a time‑horizon edge: they’re comfortable being early and uncomfortable owning consensus defensives. Expect future 13Fs to show more of this barbell — crypto and digital rails on one side, dull cash‑flow franchises on the other — with the SPAC and trust sleeve continuing to serve as a self‑funding reservoir.

For observers, the key tell going forward will be whether the finance and real‑estate weights keep bleeding lower while health care, utilities, and telecom creep higher. If they do, Mangrove is effectively calling for a regime where regulated and semi‑regulated pipes — for energy, data, payments, and even addiction treatment — outperform broad market beta, with crypto as the torque on top.

Rotation

How the book's themes shifted

Portfolio weight by theme, this quarter versus last.

2025 Q42026 Q1Finance & Real EstateFinance & Real Estate — 2025 Q4: 32.9%32.9%Finance & Real Estate — 2026 Q1: 20.8%20.8% −12.1ptConsumer (Disc + Staples)Consumer (Disc + Staples) — 2025 Q4: 24.5%24.5%Consumer (Disc + Staples) — 2026 Q1: 21.1%21.1% −3.4ptPipes & Regulated (Utilities + Industrials + Telecom)Pipes & Regulated (Utilities + Industrials + Telecom) — 2025 Q4: 24%24%Pipes & Regulated (Utilities + Industrials + Telecom) — 2026 Q1: 25.9%25.9% +1.9ptCrypto & Unclassified OptionalityCrypto & Unclassified Optionality — 2025 Q4: 9.8%9.8%Crypto & Unclassified Optionality — 2026 Q1: 16.8%16.8% +7.0ptHealth CareHealth Care — 2025 Q4: 0%0%Health Care — 2026 Q1: 8.7%8.7% +8.7ptTechnologyTechnology — 2025 Q4: 8.7%8.7%Technology — 2026 Q1: 6.7%6.7% −2.0pt
Portfolio weight by theme, 2025 Q4 (estimated at current prices) vs 2026 Q1.

Frequently asked questions

What did Mangrove Partners Im Llc buy in 2026-Q1?+

Mangrove’s biggest new buys in 2026-Q1 were Indivior Pharmaceuticals, Grayscale Ethereum Staking (ETH), ONEOK, Keurig Dr Pepper, Union Pacific, Genuine Parts, and several new SPACs such as HAVA, CTAAU, KTWO, RFAM, GIXXU, SCII, XFLHU, IGAC, and IRHO.

What is Mangrove Partners Im Llc’s largest holding by portfolio weight?+

Indivior Pharmaceuticals is the largest disclosed position at 6.76% of the reported 13F portfolio, slightly ahead of Atmus Filtration (6.04%) and Grayscale Ethereum Staking (5.71%).

How is Mangrove Partners Im Llc rotating its sector exposure?+

The fund is reducing exposure to finance, real estate, and consumer discretionary while increasing allocations to health care, telecom, utilities, consumer staples, and an “unclassified” bucket dominated by crypto and SPAC-related holdings.

Is Mangrove Partners Im Llc bullish on cryptocurrencies?+

Yes. A new 5.71% position in Grayscale Ethereum Staking and an increased stake in Bitwise Solana Staking ETF signal a deliberate crypto allocation, even as ETH currently trades below the fund’s average cost.

How did Mangrove Partners Im Llc perform over the latest quarter and longer term?+

The 13F portfolio was down 4.45% in 2026-Q1, but the weighted 3-year annualized return is 32.89% (134.67% cumulative) and the 5-year annualized return is 22.02% (170.48% cumulative), indicating strong multi-year performance despite recent volatility.

What role do SPACs play in Mangrove Partners Im Llc’s portfolio?+

Mangrove holds a wide basket of SPAC and blank-check names, generally near trust value with modest gains versus cost. The quarter’s minimal trims and new small entries suggest the SPAC book is used as a low‑risk optionality and funding sleeve rather than a high‑conviction growth engine.

More 13F analyses

View all